

---

---

**SECURITIES AND EXCHANGE COMMISSION**

WASHINGTON, D.C. 20549

**FORM 6-K**

REPORT OF FOREIGN PRIVATE ISSUER  
PURSUANT TO RULE 13a-16 OR 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934

*For the month of September 2011*

---

**BioLineRx Ltd.**

(Translation of Registrant's name into English)

---

P.O. Box 45158  
19 Hartum Street  
Jerusalem 91450, Israel

(Address of Principal Executive Offices)

---

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934:

Yes  No

---

On September 16, 2011, the Registrant will issue the press release which is filed as Exhibit 1 to this Report on Form 6-K. This report on Form 6-K is being incorporated by reference into all effective registration statements filed by us under the Securities Act of 1933.

---

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**BioLineRx Ltd.**

By: /s/Philip Serlin

Philip Serlin  
Chief Financial and Operating Officer

Dated: September 15, 2011

---

---



FOR IMMEDIATE RELEASE

**BioLineRx to Present at Annual UBS Global Life Sciences  
Conference in New York on September 21<sup>st</sup>**

---

**Jerusalem, September 16, 2011** - BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, today announced that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 2011 UBS Global Life Sciences Conference in New York.

Dr. Savitsky and Mr. Serlin are currently scheduled to present at 9:30 a.m. ET on Wednesday, September 21<sup>st</sup>. The presentation will be broadcast over the Internet as a "live" listen only Webcast.

To listen, please go to <http://www.biolinerx.com/default.asp?pageid=63&itemid=89>. An archive of the event will also be available for those unable to listen live.

In addition, investors attending the conference that wish to meet with Dr. Savitsky and Mr. Serlin for a one-on-one meeting should contact their UBS representative.

**About BioLineRx**

BioLineRx Ltd. is a publicly-traded biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx's current portfolio consists of five clinical stage candidates: BL-1020 for schizophrenia is in Phase II/III clinical trials; BL-1040 for treatment of patients following a myocardial infarction has completed a Phase I/II study and has been out-licensed to Ikaria Inc. for a total deal value of \$282.5 million, in addition to sales royalties; BL-5010 for non-surgical removal of skin lesions has completed a Phase I/II study; BL-1021 for neuropathic pain is in Phase I development; and BL-7040 for treating Inflammatory Bowel Disease (IBD) has completed Phase I. In addition, BioLineRx has nine products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases.

BioLineRx's business model is based on acquiring molecules mainly from biotechnological incubators and academic institutions. The Company performs feasibility assessment studies and development through pre-clinical and clinical stages, with partial funding from the Israeli Government's Office of the Chief Scientist (OCS). The final stage includes partnering with medium and large pharmaceutical companies for advanced clinical development (Phase III) and commercialization. For more information on BioLineRx, please visit [www.biolinerx.com](http://www.biolinerx.com).

---

**Contacts:**

Garth Russell / Todd Fromer  
KCSA Strategic Communications  
212-682-6300  
[Grussell@kcsa.com](mailto:Grussell@kcsa.com) / [TFromer@kcsa.com](mailto:TFromer@kcsa.com)

---